U.S. Markets close in 4 hrs 23 mins

Pressure BioSciences, Inc. (PBIO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.7100+0.0200 (+1.18%)
As of 10:21AM EDT. Market open.
Sign in to post a message.
  • C
    Carl Decicco
    The great technologies are not enough. So the good news is that filing on the extension is October 31 on the potential merger. Should see something hopefully this week or next week since Saturday is the 31st.
    Bullish
  • M
    Mad_Ratter
    Anyone have an update regarding the mergers into Availa Bio? ...this is taking longer to close than initially forecasted.
  • S
    Scott
    Pressure BioSciences Stock Gains Momentum: Should You Get In? https://twitter.com/PennyStocksN/status/1290997491249356800
  • G
    Getmoney
    This ones a winner for sure. After reading everything they got coming. This should explode lowest cbd float I know of. 1.75 million shares 😂 To the moon
  • B
    Bill
    Management if your reading now is the time to be knocking on doors for you shear technology for CBD oil!

    Interest in pot-infused drinks is soaring now that cannabis is legal in Canada and hemp-derived CBD is legal in the U.S. Canadian pot company Canopy Growth Corp. is spending up to $150 million on a facility in New York to extract CBD from hemp.

    Constellation Brands Inc., maker of Corona beer, has invested $3.8 billion in Canopy Growth, while Molson Coors Brewing Co. has started a joint venture with Quebec-based Hexo Corp. to sell nonalcoholic cannabis drinks. Even Coca-Cola Co. has said it’s interested in CBD-infused beverages, although it doesn’t have immediate plans to enter the market.

    Plant-based CBD also can be found in personal-care products including moisturizing creams to deodorants and soaps, mostly made by small manufacturers.
  • B
    Bill
    January 24, 2019
    Record Number of Scientific Papers Citing the Significant Benefits of Pressure BioSciences' PCT Platform Published in 2018
    https://ir.pressurebiosciences.com/press-releases/detail/297/record-number-of-scientific-papers-citing-the-significant
    Record Number of Scientific Papers Citing the Significant Benefits of Pressure BioSciences' PCT Platform Published in 2018
    ir.pressurebiosciences.com
  • B
    Bill
    After Developing A Revolutionary New Nanoemulsion Technology For CBD Oil, Pressure Biosciences Is Worth Watching

    https://seekingalpha.com/article/4247839-developing-revolutionary-new-nanoemulsion-technology-cbd-oil-pressure-biosciences-worth
    Over the past several months, Pressure Biosciences has developed a proprietary shearing technology, which uses high pressure to create nanoemulsions of water an
    Over the past several months, Pressure Biosciences has developed a proprietary shearing technology, which uses high pressure to create nanoemulsions of water an
    seekingalpha.com
  • B
    Bill
    looks as though they have some cash now to push forward and get this tech. out to major MJ companies.
    13. Offering and Sales Amounts
    Total Offering Amount $ USD x Indefinite
    Total Amount Sold $ 17459551 USD
    Total Remaining to be Sold $ USD x Indefinite

    Clarification of Response (if Necessary)
    From May 2, 2018 through March 6, 2019, the Company sold the securities detailed in Item 9 for a total purchase price of $4,288,000. During the same period, the company converted debt equal to $13,171,551 into the securities detailed in Item 9.

    14. Investors
    o Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
    Number of such non-accredited investors who already have invested in the offering

    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: 43

    15. Sales Commissions & Finders' Fees Expenses
    Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
    Sales Commissions $ 416300 USD o Estimate
    Finders' Fees $ 0 USD o Estimate

    Clarification of Response (if Necessary)
    Warrants for 318,680 shares with an exercise price of $3.50 per share were issued to Garden State as compensation in addition to their sales commissions.

    Filing link:
    https://ir.pressurebiosciences.com/sec-filings?page=1#
    All Filings
    ir.pressurebiosciences.com
  • J
    Jay
    Looks to me like a classic pump and dumper: no earnings, no profits and a stock that has worked its way down from 350 to 3 over the years. Only 17 employees left to rip off the stockholders by collecting paychecks from the financial corpus.
  • B
    Bill
    Consumers Turn to CBD Products Due to their Non-Psychoactive Nature NEW YORK, Feb. 8, 2019 /PRNewswire
    Cannabidiol, or CBD-based, products are appearing everywhere throughout the U.S., whether it's for healthcare and wellness, beauty, pets, medicinal, or even just purely recreational use. CBD is known to offer therapeutic effects just like tetrahydrocannabinol, or THC, however, CBD is the non-psychoactive derivative of cannabis. CBD is also legally available within the U.S. as long as it contains 0.3% or less THC, making it very accessible for consumers. Due to its current status under federal law, CBD is expected to be the more explosive market compared to its counterparts. According to data compiled by Brightfield Group, the U.S. hemp CBD market is expected to reach USD 22 Billion by 2022, outpacing the rest of the cannabis market combined. Recently, the U.S. Food and Drug Administration decided to delist CBD as a Schedule 1 drug. Shortly after, the U.S. House passed the Farm Bill, allowing for the cultivation of hemp, which CBD is primarily derived from. The passing of these two legislations positions the industry to be overly attractive for investors and businesses.
    Various types of businesses are seen entering into the CBD industry as well. Products are most commonly found in forms of oils, tinctures, and concentrates, but the recent shift in the marketplace has caused new sectors to dip their toes into the market. Products such as beverages, creams and flowers are becoming widely popular whether they are being used for medicinal or recreational purposes. "CBD is the next healthcare phenomenon," said Bethany Gomez, Managing Director at Brightfield Group. "Over the past decade I've covered a wide range of consumer markets, from foods and drinks to telecom, gaming and even cannabis. I have never seen anything like the explosion that we're seeing right now in CBD, even with the bizarre legal gray area where CBD now operates."
  • T
    TMWSIY
    I got out today. The stock has been on a slide for years. Hope I get proven wrong with everyone still invested.
  • P
    Pityfuk
    Does this latest deal seem a bit like birds of a feather flocking together?

    Not a warm fuzzy feeling looking at history of any of the people involved in these
    companies.

    This looks like a setup for continued disaster.

    Pressure BioSciences Announces Planned Name Change to "Availa Bio" Following Completion of Cannaworx and SkinScience Labs Transactions
  • B
    Bill
    $PBIO CEO Ric Schumacher of Pressure BioSciences, Inc. (OTCQB: PBIO), returns to Stock Day to discuss holding over 20 patents that utilize high pressure, the many applications in life-sciences, and the multiple instruments that they create for various industries including nutraceuticals.
    The CEOs interviewed on the Stock Day Podcast
    https://upticknewswire.com/featured-interview-ceo-ric-schumacher-of-pressure-biosciences-inc-otcqb-pbio-11/
    CEO Ric Schumacher of Pressure BioSciences, Inc., rejoins the show to talk in detail about their new technological developments with the UST system and it's ability to turn non-soluble materials soluble; including CBD oil.
    CEO Ric Schumacher of Pressure BioSciences, Inc., rejoins the show to talk in detail about their new technological developments with the UST system and it's ability to turn non-soluble materials soluble; including CBD oil.
    upticknewswire.com
  • M
    Myles  Banyon
    This company has more PR's than San Juan City.
  • D
    Droidboy
    Is there anyway to short this?
  • M
    Myles  Banyon
    I feel for long term shareholders. I suggest reading the 10K
  • B
    Bill
    Pressure Biosciences (OTCMKTS:PBIO) was upgraded by research analysts at ValuEngine from a “hold” rating to a “buy” rating in a note issued to investors on Monday. Shares of OTCMKTS PBIO traded up $0.37 during trading on Monday, hitting $2.67. The co
    Pressure Biosciences (OTCMKTS:PBIO) was upgraded by research analysts at ValuEngine from a “hold” rating to a “buy” rating in a note issued to investors on Monday. Shares of OTCMKTS PBIO traded up $0.37 during trading on Monday, hitting $2.67. The co
    www.fairfieldcurrent.com
  • j
    joe
    1.82 was a low for today, are we looking at another reverse split to get the price back up?
  • G
    Gregory
    Why does pbio appear to have stopped trading activity? Anyone know? Last trade was 09/07/18, nothing since, and this is Tuesday 09/11/18